Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | ECE1 | P42892 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 5/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156911 | 0.93 | GAA (0.58) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL3922780 | 0.92 | MEN1 (0.45) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL4394882 | 0.91 | MEN1 (0.53) | MEN1GAAKMT2ATDP1EPHX1 | |
| Succinic Acid SCHEMBL29429364 | 0.91 | GAA (0.56) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL21834873 | 0.91 | GAA (0.56) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL9554443 | 0.90 | TDP1 (0.57) | MEN1GAAKMT2ATDP1CA1 | |
| SCHEMBL5840460 | 0.88 | MEN1 (0.46) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL7514267 | 0.88 | MEN1 (0.50) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL12656066 | 0.87 | TDP1 (0.61) | MEN1GAAKMT2ATDP1EPHX1 | |
| SCHEMBL16061043 | 0.86 | MEN1 (0.53) | MEN1GAAKMT2ATDP1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080608-B1 | MASS LABELS | ELECTROPHORETICS LTD (GB) | 2023-02-01 | — | — | EP | disclosed |
| US-9527964-B2 | Thermoplastic elastomers containing an oligopeptide hard component | THE UNIVERSITY OF AKRON (US) | 2016-12-27 | — | — | US | disclosed |
| US-20150141574-A1 | THERMOPLASTIC ELASTOMERS CONTAINING AN OLIGOPEPTIDE HARD COMPONENT | THE UNIVERSITY OF AKRON (US) | 2015-05-21 | — | — | US | disclosed |
| EP-1313703-B1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | HOFFMANN LA ROCHE (CH) | 2008-02-13 | — | — | EP | disclosed |
| CN-1227230-C | Prodrugs to NMDA receptor ligands | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | CN | disclosed |
| CN-1447793-A | Prodrugs to NMDA receptor ligands | HOFFMANN LA ROCHE (CH) | 2003-10-08 | — | — | CN | disclosed |
| EP-1313703-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| US-6407235-B1 | A NMDA (N-METHYL-D-ASPARTATE)-RECEPTOR-SUBTYPE SELECTIVE BLOCKERS; PRODRUGS HAVE IMPROVED SOLUBILITY AND ARE HYDROLYZED IN VIVO; FOR EXAMPLE, THE 4-AMINOMETHYL-BENZOIC ACID ESTER OF THE PHENOL, OR THE PHOSPHATE ESTER | HOFFMANN-LA ROCHE INC. | 2002-06-18 | — | — | US | disclosed |
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | EVOTEC INTERNATIONAL GMBH (DE) | 2002-04-04 | — | — | US | disclosed |
| WO-2002016321-A1 | PRODRUGS TO NMDA RECEPTOR LIGANDS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040037-A1 | Prodrug acid esters of [2-(4-benzyl-3-hydroxy-piperidin-1-yl)-ethansulfonyl]phenol | HAO2, CYP2B6, CBR1 | MEN1 4382/4885GAA 1206/4885KMT2A 2738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.